Pimecrolimus/paclitaxel-eluting coronary stent - Johnson & Johnson

Drug Profile

Pimecrolimus/paclitaxel-eluting coronary stent - Johnson & Johnson

Alternative Names: Paclitaxel/pimecrolimus-eluting coronary stent - Johnson & Johnson; Symbio

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Conor Medsystems
  • Developer Conor Medsystems; Cordis Corporation
  • Class Anti-inflammatories; Diterpenes; Macrolides; Paclitaxels; Taxanes
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Coronary artery disease

Most Recent Events

  • 17 Feb 2016 No development reported - Phase-III for Coronary artery disease in Belgium (Intracoronary)
  • 17 Feb 2016 No development reported - Phase-III for Coronary artery disease in France (Intracoronary)
  • 17 Feb 2016 No development reported - Phase-III for Coronary artery disease in Germany (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top